Jacob Bell is a Senior Reporter for BioPharma Dive, with previous experience at TheStreet, Education Week, and McClatchy DC. Jacob's reporting focuses on the pharmaceutical and biotechnology industries, covering topics such as drug development, regulatory updates, and industry trends. His work has also been featured in GeeksULTD.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Jacob Bell's coverage is heavily focused on the healthcare and pharmaceutical industries, with particular attention to biotechnology. His articles often incorporate press releases and data citations, indicating a preference for factual and industry-specific information.
Given his focus on private sector announcements, Jacob may be interested in pitches related to new product launches, significant investments or acquisitions within the healthcare and biotech sectors. Furthermore, he might be open to expert commentary from professionals well-versed in various aspects of biotechnology, pharmaceuticals, neurological diseases such as ALS research or gene therapy.
As there is no specific geographic focus mentioned for Jacob's coverage area, it would be beneficial to provide globally relevant insights pertaining to the topics covered.
This information evolves through artificial intelligence and human feedback. Improve this profile .
One analyst thinks the collaboration “bodes well” for Gossamer, which has had trouble convincing investors its drug seralutinib can compete on the market.
By: Jacob Bell
After delaying an approval decision for Lilly’s donanemab, the agency now intends to hold an advisory committee meeting on June 10.
By: Jacob Bell
The deal — worth $100 million up front and potentially billions more later on — gives Takeda an exclusive option to license an Alzheimer’s vaccine and other “active immunotherapies.”
The annual forecast, which comes as Eisai and Biogen have begun submitting a more convenient form of Leqembi for approval, looks “more realistic” than previous guidance, according to Jefferies analysts.
While results indicated the drug works as intended, it didn’t have enough of an effect on a protein that’s become integral to many ALS research programs.
Forbion, a well-known backer of life sciences startups, is leading an investment round for a newly launched biotechnology company focused on diseases that affect nerve cells.
Medical experts who advise the Food and Drug Administration are not convinced MDMA is ready for general use to help treat post-traumatic stress disorder, recommending at a meeting Tuesday the agency hold off on an approval.
By: Jacob Bell, Jonathan Gardner
An experimental and closely watched medicine for Alzheimer's disease is one step closer to approval, after receiving support from a panel of experts who advise the Food and Drug Administration.
By: Jacob Bell, Jonathan Gardner
The expert committee concluded donanemab’s benefits outweigh its risks, despite some concern over the drug’s safety.
A growing cohort of biotechs, from Biohaven to Neurocrine to Jazz, hope research on ion channels will bring them new drugs and big business — much like it has done for Vertex.
(833) 317-6278 
